Evidence map›Paper›PMID 40143273›Full record

ArticleViruses2025

rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model.

Amy C Shurtleff, John C Trefry, Sheri Dubey, Melek M E Sunay, Kenneth Liu, Ziqiang Chen, Michael Eichberg, Peter M Silvera, Steve A Kwilas, Jay W Hooper and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Amy C ShurtleffUS Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA.
John C TrefryUS Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA.
Sheri DubeyMerck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA.
Melek M E SunayUS Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA.
Kenneth LiuMerck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA.
Ziqiang ChenMerck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA.
Michael EichbergMerck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA.
Peter M SilveraUS Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA.
Steve A KwilasUS Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA.ORCID 0000-0003-0383-3879
Jay W HooperUS Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA.ORCID 0000-0002-4475-0415
Shannon MartinUS Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA.
Jakub K SimonMerck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA.
Beth-Ann G CollerMerck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA.
Thomas P MonathNewLink Genetics Corp., Loop Dr #5100, Ames, IA 50010, USA.

Funding

Administration for Strategic Preparedness and Response (ASPR) N/ABiomedical Advanced Research and Development Authority (BARDA) HHSO100201700012CDefense Threat Reduction Agency HDTRA1-15-C-0058Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA N/AU.S Department of Health and Human Services (HHS) N/A
6 · The paper itself

Abstract

The recombinant vesicular stomatitis virus-Zaire Ebolavirus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP) was highly effective against Ebola virus disease in a ring vaccination trial conducted during the 2014-2016 outbreak in Guinea and is licensed by regulatory agencies including US FDA, EMA, and prequalified by WHO. Vaccination studies in a nonhuman primate (NHP) model guided initial dose selection for clinical trial evaluation. We summarize two dose-ranging studies with the clinical-grade rVSVΔG-ZEBOV-GP vaccine candidate to assess the impact of dose level on immune responses and efficacy in an NHP Ebola virus (EBOV) challenge model. Forty-six cynomolgus macaques were vaccinated with a wide range of rVSVΔG-ZEBOV-GP doses and challenged 42 days later intramuscularly with 1000 pfu EBOV. Vaccination with rVSVΔG-ZEBOV-GP induced relatively high levels of EBOV-specific IgG and neutralizing antibodies, measured using the same validated assays as used in rVSVΔG-ZEBOV-GP clinical trials. Similar responses were observed across dose groups from 1 × 10

Indexed as

Ebola VaccinesEbolavirusHemorrhagic Fever, EbolaImmunogenicity, VaccineViral Envelope ProteinsAnimalsAntibodies, NeutralizingAntibodies, ViralDisease Models, AnimalFemaleMacaca fascicularisMaleVaccinationVaccine EfficacyVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralEbola VaccinesVaccines, SyntheticViral Envelope ProteinsEbolavirusERVEBOnonhuman primatesvaccinevesicular stomatitis virus

Identifiers

PMID40143273
PMCPMC11945660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.